Implant-supported Rehabilitation With SPAL Technique or Soft Tissue Augmentation (SPALvsSTA)
Dehiscence, Alveolar Ridge Enlargement, Bone Loss, Alveolar
About this trial
This is an interventional treatment trial for Dehiscence
Eligibility Criteria
Patient-specific inclusion criteria age≥21years; good physical status (ASA1 and ASA2 according to Physical Status Classification System) (American Society of Anesthesiologists, 2010); systemic and local conditions compatible with implant placement and experimental procedures; indication to a fixed, implant-supported prosthetic rehabilitation with hard or soft tissue reconstructive procedures as part of the comprehensive oral rehabilitation plan; patient willing and fully capable to comply with the study protocol. Sextant-specific inclusion criteria To be considered as experimental, a sextant will have to fulfill all the following criteria: including at least one healed (i.e., ≥ 6 months elapsed from tooth loss) edentulous site; horizontal dimension of the edentulous ridge compatible with the primary stability of an implant of at least 3.5 mm in diameter; expected peri-implant buccal BD characterized by a height (measured as the apico-coronal height of the exposed implant surface) ≤ 5 mm or a thin (< 1 mm) peri-implant buccal bone plate as diagnosed on tridimensional planning for guided implant placement. Patient will not be eligible for the study if presenting at least one of the following exclusion criteria: Patient-specific exclusion criteria current heavy smoking (≥20 cigarettes/day for ≥6 months prior to and at the time of the surgical procedure); untreated periodontal disease prior to implant placement; history of radiation therapy in the head and neck area; history of chemotherapy; systemic disease or conditions with a documented effect on bone metabolism and/or osseous healing; past (within 6 months prior to enrolment in the study) or current treatment with any medication with a documented effect on bone metabolism and/or osseous healing; documented allergy to dental materials involved in the experimental protocol; pregnancy or lactation; history of drug or alcohol abuse. Moreover, participants immediately exited the study upon: request to withdraw from further participation; development of acute dental, peri-implant or oral conditions requiring treatment; development of conditions conflicting with the inclusion criteria listed above; failure to comply with study instructions/requirements. Site specific exclusion criteria presence of either a buccal BD > 5 mm in depth or a thick (≥ 1 mm) peri-implant buccal bone plate as clinically assessed with a periodontal probe immediately after implant placement; presence of endodontic lesions at teeth adjacent to the implant site; previous bone augmentation/preservation procedures at the designated implant areas; need for vertical bone augmentation.
Sites / Locations
- Polo OdontoiatricoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sub-Periosteal Peri-implant Augmented Layer (SPAL) technique simultaneous to implant placement
Soft Tissue Augmentation (STA) simultaneous to implant placement
In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.